MedTrace Logo

Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate

NCT02883439 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-07-13

No results posted yet for this study

Summary

The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.

Conditions

  • Bioavailability Study

Interventions

DRUG

MP29-02

local nasal application

DRUG

Fluticasone propionate

local nasal application

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    collaborator INDUSTRY

  • University of Wuerzburg

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Claus Bachert · Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02883439 on ClinicalTrials.gov